# US 2002/0160526 A1 · Process for isolating a target biological material, capture phase, detection phase and reagent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0160526 A1
- Document ID: US20020160526A1
- Status: Published application
- Kind: A1
- Application number: 09/403,085
- Filed: 2000-01-07
- Published: 2002-10-31
- Earliest claimed: 1997-04-16
- Inventors: ABDELHAMID ELAISSARI; DAVID DURACHER; CHRISTIAN PICHOT; FRANCOIS MALLET; ARMELLE NOVELLI-ROUSSEAU
- Web page: https://patentgrep.com/patent/US20020160526A1

## CPC

- C08F 220/54: Amides {, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide}
- G01N 33/54313: {the carrier being characterised by its particulate form}
- G01N 33/54326: {Magnetic particles}
- G01N 33/54353: {with ligand attached to the carrier via a chemical coupling agent (coatings G01N33/54393)}
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention concerns a method for isolating a target biological material contained in a sample, consisting in the following steps: providing a capture phase, in microparticulate or linear form, consisting of at least a first particulate or linear polymer, with apparent hydrophile character and first complexing groups, the latter being bound by co-ordination to a first transition metal, which is itself bound to a frist biological entity capable of specifically recongnising the target biological material; contacting said target biological material with at least the capture phase; and detecting the capture phase-target biological material complex, optionally with a detection phase, in microparticulate or linear form, and consisting of at least a second particulate or linear polymer, with apparent hydrophile character and second complexing groups, the latter being bound by co-ordination to a second transition metal, which is itself bound to a second biological entity capable of specifically recognizing the target biological material, and a marker.

## Claims

### Claim 1

Process for isolating a target biological material contained in a sample, according to which a capture phase is used, said target biological material being placed in contact with at least the capture phase, and the capture phase/target biological material complex is detected,
said process being characterized in that,
the capture phase is in microparticulate or linear form and consists of at least one first particulate or linear polymer, with a hydrophilic apparent nature and first complexing groups, these groups being linked by coordination to a first transition metal, which is itself linked to a first biological species capable of specifically recognizing the target biological material.

### Claim 2 (depends on 1)

Process according to claim 1, characterized in that the capture phase comprises a marker in order to obtain a detection phase.

### Claim 3 (depends on 1)

Process according to claim 1, characterized in that a detection phase is also used, which is in microparticulate or linear form and consists of at least one second particulate or linear polymer, of hydrophilic apparent nature, and second complexing groups, these groups being linked by coordination to a second transition metal, which is itself linked to a second biological species capable of specifically recognizing the target biological material, and a marker.

### Claim 4 (depends on 1, 3)

Process according to claim 1 or 3, characterized in that the first and/or the second polymer is chosen from the group of hydrophilic polymers.

### Claim 5 (depends on 4)

Process according to claim 4, characterized in that the first and/or the second polymer is a functionalized polymer obtained by polymerization of a water-soluble monomer, of acrylamide, of an acrylamide derivative, of methacrylamide or of a methacrylamide derivative, of at least one crosslinking agent and of at least one functional monomer.

### Claim 6 (depends on 5)

Process according to claim 5, characterized in that the water-soluble monomer is chosen from N-isopropylacrylamide, N-ethylmethacrylamide, N-n-propyl-acrylamide, N-n-propylmethacrylamide, N-n-isopropyl-methacrylamide, N-cyclopropylacrylamide, N,N-diethylacryl-amide, N-methyl-N-isopropylacrylamide and N-methyl-N-n-propylacrylamide, the first monomer preferably being N-isopropylacrylamide (NIPAM).

### Claim 7 (depends on 5)

Process according to claim 5, characterized in that the functional monomer corresponds to formula I below:
CH2=C(Z)−(X)m−(R)p−(Y)n (I)
in which
Z represents H, a C1-C5 alkyl radical or a benzyl, —COOH or —CO—NH—CH(CH,)2 radical,
Y represents —CH2—COOH, —N(CH2—COOH)2,
2
(CH2—COOH), or —N(CH2—CH2—NH2)2,
x represents —NH(CH2—CH2—), —N(CH2—CH2—)2, —N(CH2—COOH) (CH2—CH2—), or CH(COOH)—,
R represents a linear hydrocarbon-based chain, optionally interrupted with at least one hetero atom such as O or N,
m and p are each an integer which, independently of each other, are equal to 0 or 1, and
n is an integer ranging between 1 and 3.

### Claim 8 (depends on 7)

Process according to claim 7, characterized in that the functional monomer is chosen from carboxylic derivatives, optionally containing nitrogen, itaconic acid, acrylic derivatives and methacrylic derivatives.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Process according to any one of claims 1 to 8, characterized in that the capture phase and/or the detection phase is in microparticulate form and in that the average particle size is not more than 5 μm.

### Claim 10 (depends on 1)

Process according to claim 1, characterized in that the capture phase also comprises a flat or particulate support.

### Claim 11 (depends on 10)

Process according to claim 10, characterized in that the support is particulate and consists of an organic or inorganic, hydrophilic or hydrophobic core.

### Claim 12 (depends on 11)

Process according to claim 11, characterized in that said core is chosen from the group comprising polystyrene, silica and metal oxides.

### Claim 13 (depends on 11, 12)

Process according to claim 11 or 12, characterized in that said core also contains a magnetic compound.

### Claim 14 (depends on 11, 12, 13)

Process according to any one of claims 11 to 13, characterized in that said core is coated with said first polymer, this polymer being linear.

### Claim 15 (depends on 11, 12, 13)

Process according to any one of claims 11 to 13, characterized in that said core is coated with said polymer, said polymer being particulate.

### Claim 16 (depends on 1, 3)

Process according to claim 1 or 3, characterized in that the first and/or the second polymer is poly(N-isopropylacrylamide) and the complexing groups are derived from itaconic acid or from maleic anhydride-co-methyl vinyl ether.

### Claim 17 (depends on 1, 3)

Process according to claim 1 or 3, characterized in that the first and/or second transition metal is chosen from zinc, nickel, copper, cobalt, iron, magnesium, manganese, lead, palladium, platinum and gold.

### Claim 18 (depends on 1, 3)

Process according to claim 1 or 3, characterized in that the placing in contact of the first biological species with the capture phase and/or the placing in contact of the second biological species with the detection phase is carried out at a pH above or equal to the isoelectric point of said first and second biological species, respectively.

### Claim 19 (depends on 1, 3)

Process according to claim 1 or 3, characterized in that the first and/or the second biological species is rich in histidine and/or cysteine.

### Claim 20 (depends on 1, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

Process according to claim 1 and any one of claims 4 to 19, characterized in that an agglutination reaction is used.

### Claim 21 (depends on 2, 3)

Process according to claim 2 or 3, characterized in that the marker for the detection phase is chosen from the group consisting of an enzyme, biotin, iminobiotin, a fluorescent component, a radioactive component, a chemiluminescent component, an electron-density component, a magnetic component, an antigen, a hapten and an antibody.

### Claim 22 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21)

Process according to claim 2 or 3 and any one of claims 4 to 19 or 21, characterized in that the ELISA technique is used.

### Claim 23

Phase for capturing a target biological material, characterized in that it is in microparticulate or linear form and consists of at least one first particulate or linear polymer, of hydrophilic apparent nature, and first complexing groups, these groups being linked by coordination to a first transition metal, which is itself linked to a first biological species capable of recognizing the target biological material.

### Claim 24

Phase for detecting a target biological material, characterized in that it is in microparticulate or linear form and consists of at least one second particulate or linear polymer, of hydrophilic apparent nature, and second complexing groups, these groups being linked by coordination to a second transition metal, which is itself linked to a second biological species capable of recognizing the target biological material, and a marker.

### Claim 25 (depends on 23, 24)

Reagent for isolating a target biological material, comprising a capture phase according to claim 23 and/or a detection phase according to claim 24.
